Efficacy of vaccination against staphylococcal mastitis: a review and new data

Infection of the heifer mammary gland with common mastitis pathogens, particularly staphylococci, prior to calving is well documented. Efforts to eliminate pre-partum intramammary infections (IMI) in heifers have focused primarily on intramammary antibiotic therapy shortly before or at the time of calving. Few studies have evaluated vaccination of heifers against staphylococcal mastitis. The objectives of the present study were to evaluate the efficacy of a commercially available Staphylococcus aureus bacterin in protecting against staphylococcal IMI (S. aureus and coagulase-negative staphylococci (CNS)), to study the effect of vaccination on milk SCC, and to evaluate the milk antibody isotype response to vaccination using a lactating cow model. Ninety Holstein-Friesian lactating dairy cows of various parities were systematically assigned to a vaccinated (n=44) or control (n=46) group. Vaccinates received two 5 ml doses of the bacterin 14 days apart starting on day 0. Quarter milk samples for bacterial culture were collected prior to each vaccination and approximately monthly thereafter for 6 months. Composite milk samples were collected on days 0, 14, 28, 49 and 70 for IgA, IgG(1), IgG(2), and IgM determinations and somatic cell count. No animals in either group developed a new S. aureus IMI after vaccination. The numbers of mammary quarters that developed a new CNS IMI, time to new CNS IMI, milk somatic cell count, and milk antibody isotype sample-to-positive ratio did not significantly differ between groups (P>0.05). In a herd with a 3% prevalence of S. aureus IMI and a 30% prevalence of CNS IMI, the vaccine did not reduce the new staphylococcal IMI rate. There may be insufficient vaccine-induced opsonizing antibody in milk to facilitate phagocytosis and clearance of staphylococci from the mammary gland.